Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 2/2016

01-04-2016 | Research Article

Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients

Authors: Nazan Yuce-Artun, Bora Baskak, Erguvan Tugba Ozel-Kizil, Hatice Ozdemir, Zuhal Uckun, Halise Devrimci-Ozguven, Halit Sinan Suzen

Published in: International Journal of Clinical Pharmacy | Issue 2/2016

Login to get access

Abstract

Background Genetic polymorphisms in CYP2B6 and CYP2C19 may cause variability in the metabolism of sertraline, a widely used antidepressant in major depressive disorder treatment. Objective This study investigates the impact of CYP2B6*4 (785A > G), CYP2B6*9 (516G > T), CYP2B6*6 (516G > T + 685G > A) CYP2C19*2 (685G > A), CYP2C19*17 (−3402C > T) polymorphisms on plasma concentrations of sertraline and N-desmethyl sertraline in major depression patients treated with sertraline [n = 50]. Setting Participants were patients who admitted to an adult psychiatry outpatient unit at a university hospital. These were DSM-IV major depression diagnosed patients with a stable sertraline medication regimen [for at least one month]. Methods CYP2B6*4 (rs 2279343; 785A > G), CYP2B6*9 (516G > T; rs 3745274), CYP2B6*6 (516G > T + 685G > A) CYP2C19*2 (rs 4244285; 685G > A), CYP2C19*17 (rs 11188072; −3402C > T), polymorphisms were analyzed by polymerase chain reaction and restriction fragment length polymorphism. Plasma concentrations were measured by high-performance liquid chromatography in patients treated with SERT. Main outcome measure The distribution of CYP2B6*4, *6, *9 and CYP2C19*2, *17 among patient group and the association between genotype and sertraline metabolism. Results Sertraline, N-desmethyl sertraline, N-desmethyl sertraline/sertraline and dose-adjusted plasma concentrations were statistically compared between individuals with wild-type and variant alleles both for CYP2B6 and CYP2C19 enzymes. The mean N-desmethyl sertraline/sertraline value, was significantly lower in all subgroups with *6 and *9 variant alleles (p < 0.05). Sertraline/C values were significantly higher (p <  0.05) and N-desmethyl sertraline/C values were lower in all subgroups with *6 and *9 variant alleles compared to wild-type subgroup. Conclusion CYP2B6*6 and *9 variant alleles had a significant decreasing effect on sertraline metabolism in major depression patients which might result as variations in sertraline therapy.
Literature
1.
Mauri MC, Fiorentini A, Cerveri G, Volonteri LS, Regispani F, Malvini L, et al. Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Hum Psychopharmacol. 2003;18:385–8.CrossRefPubMed
2.
de Leon J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectr. 2006;11(Suppl 3):8–12.PubMed
3.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–91.CrossRefPubMed
4.
5.
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48:689–723.CrossRefPubMed
6.
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet. 2009;48:761–804.CrossRefPubMed
7.
Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89–295.CrossRefPubMed
8.
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.CrossRef
9.
Murdoch D, McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive compulsive disorder. Drugs. 1992;44:604–24.CrossRefPubMed
10.
Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, et al. Results of a double-blind, placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive compulsive disorder. Psychopharmacol Bull. 1990;26:279–84.PubMed
11.
Cohn CK, Shrivestava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990;51(Suppl B):28–33.PubMed
12.
Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, et al. Double-blind, parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289–95.CrossRefPubMed
13.
Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. A 1-year double-blind, placebo-controlled, fixed-dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57–65.CrossRefPubMed
14.
Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, et al. Antidepressant efficacy of sertraline: a double-blind, placebo and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51(Suppl B):18–27.PubMed
15.
Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, et al. Sertraline safety and efficacy in major depression: a double-blind, fixed-dose comparison with placebo. Biol Psychiatry. 1995;38:592–602.CrossRefPubMed
16.
Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217–22.CrossRefPubMed
17.
Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry. 1988;49(Suppl):46–51.PubMed
18.
Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101:354–9.CrossRefPubMed
19.
Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol. 1991;6:11–21.CrossRefPubMed
20.
Reis M, Aberg-Wistedt A, Agren H, Höglund P, Akerblad AC, Bengtsson F. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol. 2004;19:283–91.CrossRefPubMed
21.
Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42–56.CrossRefPubMed
22.
Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes mediating sertraline biotransformation: seeking attribution. J Clin Psychopharmacol. 1999;19:489–93.CrossRefPubMed
23.
Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999;27:763–6.PubMed
24.
Xu ZH, Wang W, Zhao XJ, Huang SL, Zhu B, He N, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol. 1999;48:416–23.CrossRefPubMedPubMedCentral
25.
Obach RS, Cox LM, Tremaine LM. Sertraline a P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33:262–70.CrossRefPubMed
26.
Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743–59.CrossRefPubMed
27.
Lang T, Klein K, Fisher J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399–415.CrossRefPubMed
28.
de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594–8.PubMed
29.
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103–13.CrossRefPubMed
30.
First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV clinical version [SCID-I/CV]. American Psychiatric Pres: Washington DC; 1997.
31.
Pang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol. 2004;58(3):332–5.CrossRefPubMed
32.
Yuce-Artun N, Kose G, Suzen HS. Allele and genotype frequencies of CYP2B6 in a Turkish population. Mol Biol Rep. 2014;41(6):3891–6.CrossRefPubMed
33.
Yuce-Artun N, Ozel Kizil ET, Baskak B, Devrimci Ozguven H, Duydu Y, Suzen HS. Determination of sertraline and its metabolite by high-pressure liquid chromatography in plasma. Rev Roum Chim. 2015;60(5–6):543–8.
34.
Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 [CYP2B6]: advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24.CrossRefPubMedPubMedCentral
35.
Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genom. 2005;15(12):861–73.CrossRef
36.
Cho JY, Lim HS, Chung JY, et al. Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos. 2004;32:1341–4.CrossRefPubMed
37.
Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006;62:267–75.CrossRefPubMedPubMedCentral
38.
Hofmann MH, Blievernicht JK, Klien K, Saussele T, Schaeffeler E, Schwab M, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G > T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CY2B6 in liver. J Pharmacol Exp Ther. 2008;325:284–92.CrossRefPubMed
39.
Rudberg I, Hermann M, Refsum H. Molden E Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol. 2008;64:1181–8.CrossRefPubMed
40.
Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999;66:185–92.CrossRefPubMed
41.
Uckun Z, Baskak B, Ozel-Kizil ET, Ozdemir H, Devrimci Ozguven H, Suzen HS. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. J Clin Pharm Ther. 2015;40:672–9.CrossRefPubMed
Metadata
Title
Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients
Authors
Nazan Yuce-Artun
Bora Baskak
Erguvan Tugba Ozel-Kizil
Hatice Ozdemir
Zuhal Uckun
Halise Devrimci-Ozguven
Halit Sinan Suzen
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0259-8

Other articles of this Issue 2/2016

International Journal of Clinical Pharmacy 2/2016 Go to the issue

Research Article

Pharmacists’ knowledge and interest in developing counseling skills relating to oral contraceptives

Research Article

Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar

Research Article

Free phenytoin assessment in patients: measured versus calculated blood serum levels

Research Article

The influence of organisational climate on care of patients with schizophrenia: a qualitative analysis of health care professionals’ views

Erratum

Erratum to: Seeking to understand: using generic qualitative research to explore access to medicines and pharmacy services among resettled refugees

Short Research Report

A multidimensional antimicrobial stewardship intervention targeting aztreonam use in patients with a reported penicillin allergy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits